PyrAmes platforms will provide options to continuously monitor blood pressure cNIBP for patients of all ages.
could benefit from BP monitoring but would not receive an arterial line because it is invasive and costly.2
50% of adults are affected by high blood pressure in the US, increasing their mortality rates.3
Raised blood pressure (BP) is responsible for 7.6 million deaths worldwide annually.4
cNIBP has the potential for early detection of conditions within preterm infants and adults.
1. Quan, X.; Liu, J.; Roxlo, T.; Siddharth, S.; Leong, W.; Muir, A.; Cheong, S.-M.; Rao, A. Advances in Non-Invasive Blood Pressure Monitoring. Sensors 2021, 21, 4273. https://doi.org/10.3390/s21134273
2. Haidari, E. S., Lee, H. C., Illuzzi, J. L., Phibbs, C. S., Lin, H., & Xu, X. (2020). Hospital variation in admissions to neonatal intensive care units by diagnosis severity and category. Journal of Perinatology, doi:10.1038/s41372-020-00775-z
PyrAmes’ novel Boppli™ device enables continuous, noninvasive blood pressure monitoring (cNIBP) for the hospital’s most fragile patients. PROVIDENCE, RI and CUPERTINO, CA, September 13, 2022 — Sentec and PyrAmes have established a commercial partnership to bring Boppli, PyrAmes’ first-of-its-kind continuous noninvasive blood pressure device, to neonatal intensive care teams throughout the United States. Boppli has received Breakthrough Device Designation from the US Food & Drug Administration (FDA) and will be available after FDA 510(k) clearance, which is anticipated in the first half of 2023. “We are excited to join forces with Sentec to commercialize our Boppli product,” said Xina Quan, PhD, Co-Founder and CEO of PyrAmes. “This important step enables us to bring our breakthrough technology to market and transform patient care. We believe Sentec is an ideal partner for us in the NICU, given our companies’ shared mission and focus on noninvasive technologies to enable better healthcare delivery.”In the neonatal intensive care unit (NICU) today, a baby’s blood pressure is either monitored continuously through an invasive arterial catheter or intermittently through cuff measurements. Both techniques present certain clinical challenges. The Boppli™ platform offers a new solution to overcome those challenges. (more…)
PyrAmes chosen from 1,300+ applicants to collaborate with LG on innovative connected health products. CUPERTINO, CA, February 10, 2022 -- PyrAmes, Inc., a digital healthcare company focused on innovative products for continuous blood pressure monitoring, today announced its selection by the LG Electronics North American Innovation Center, LG NOVA in its inaugural cohort of startups selected in its large-scale Mission for the Future global challenge competition. Chosen from a group of over 1,300 applicants, the “First 50” companies represent new developments in several areas including Connected Health, and will work with the LG NOVA team on their business concepts. (more…)
The PyrAmes Boppli™ device is featured on page 11 in the Winter 2022 edition of Neonatal Intensive Care: The Journal of Perinatology-Neonatology. The article focuses on how the Boppli is being developed to meet the need for continuous, non-invasive blood pressure monitoring in the neonatal intensive care unit (NICU).
2020 FDA Breakthrough Device Designation
Founding Member of CDC National Hypertension Control Roundtable
2020 SWPDC Pediatric Device Award, Member of SWPDC
2019 MedTech Innovator Accelerator & 2020 NCC-PDI MedTech Innovator Pediatric Accelerator
Exponential Medicine 2019 One to Watch Award